Evaluation of the Performance of QuantiFERON-TB Gold Plus Assay in Human Immunodeficiency Virus Infection

Basit Öğe Kaydı
dc.contributor.authorDuman, Melike Yasar
dc.contributor.authorCavusoglu, Cengiz
dc.contributor.authorAltuglu, Imre
dc.contributor.authorZeytinoglu, Aysin
dc.contributor.authorGokengin, Ayse Deniz
dc.contributor.authorAydogan, Tansu Gulbahar
dc.contributor.authorOrman, Mehmet Nurullah
dc.date.accessioned2024-08-25T18:48:29Z
dc.date.available2024-08-25T18:48:29Z
dc.date.issued2022
dc.departmentEge Üniversitesien_US
dc.description.abstractIntroduction: Individuals co-infected with human immunodeficiency virus (HIV) and Mycobacterium tuberculosis have an increased risk of the reactivation of latent tuberculosis (TB) infection (LTBI) to active TB. The addition of peptides to stimulate CD8+ T cells is expected to increase the sensitivity of the QuantiFERON((R))-TB Gold Plus (QFT-Plus) assay in detecting LTBI and TB infection in patients. This study aimed to determine the prevalence of LTBI in patients with HIV infection in our region and to evaluate the possible factors that may interfere with the performance of the QFT-Plus assay in HIV infection. Materials and Methods: The study included 132 HIV-positive and 133 HIV-negative cases presented to the Ege University Medical Faculty Hospital between January 2016 and December 2019. Demographic and clinical data and laboratory/culture results were obtained from the mycobacteriology laboratory and hospital database. Results: QFT-Plus positivity rates were 30.1% (40/133) in the HIV-negative and 21.2% (28/132) in HIV-positive groups. The indeterminate results of the HIV-positive and HIV-negative groups were 4.5% and 3%, respectively. The CD4+ T cell count was below 200/mm3 in five of the six patients in the HIV-positive group with indeterminate results, and the median lymphocyte count was significantly lower. Although no significant difference was found between the median lymphocyte counts of the HIV-positive and HIV-negative group, the positivity rates and secreted interferon (IFN)-gamma levels were lower, and the indeterminate results were higher in the HIV-positive group than in the HIV-negative group, but the difference was not significant. The rate of QFT-Plus positivity was 32.4% in patients with a viral load below 10,000 copies/ml and 16.1% in patients with a viral load above 10,000 copies/ml (p=0.047). Conclusion: The positivity rates and secreted IFN-. levels were lower, and the indeterminate results were higher in the HIV-positive group than in the HIV-negative group. The addition of TB2 tube to the QFT-Plus assay could contribute to the sensitivity of the test in both HIV-positive and HIV-negative individuals with LTBI.en_US
dc.identifier.issn2147-673X
dc.identifier.scopus2-s2.0-85149475581en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.urihttps://hdl.handle.net/11454/102292
dc.identifier.volume11en_US
dc.identifier.wosWOS:000964556200002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherGalenos Publ Houseen_US
dc.relation.ispartofMediterranean Journal of Infection Microbes and Antimicrobialsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240825_Gen_US
dc.subjectQuantiFERON-TB Gold Plusen_US
dc.subjectactive tuberculosisen_US
dc.subjecthuman immunodeficiency virusen_US
dc.subjectlatent tuberculosis infectionen_US
dc.subjectMycobacterium tuberculosisen_US
dc.subjectTuberculin Skin-Testen_US
dc.subjectAntiretroviral Therapyen_US
dc.subjectCell Responsesen_US
dc.subjectRisken_US
dc.subjectDiagnosisen_US
dc.titleEvaluation of the Performance of QuantiFERON-TB Gold Plus Assay in Human Immunodeficiency Virus Infectionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu